Modality Dx

PRESS RELEASE Porltand, OR, June 17 –Diabetomics has been rebranded Modality Dx. Founded by Dr. Srinivasa Nagalla, Modality Dx is an innovator in rapid test technologies for risk assessment and diagnosis in maternal health, diabetes and autoimmune disease. “Throughout my career, I’ve seen firsthand the great need for more preventive healthcare solutions,” said Dr. Nagalla. “Too […]

https://www.edent1fi.eu/our-partners

Sokratous, N., Wright, A., Syngelaki, A., Kakouri, E., Laich, A. and Nicolaides, K.H. (2023), Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks’ gestation. Ultrasound Obstet Gynecol. Accepted Author Manuscript. Sokratous, N., Bednorz, M., Syngelaki, A., Wright, A., Nicolaides, K.H. and Kametas, N.A. (2023), Prediction of superimposed pre-eclampsia by serum glycosylated

Diabetomics has developed the first rapid point-of-care test for the autoimmune biomarker anti-citrullinated albumin (ACA). The ACA test compliments the current ACCP (anti-cyclic citrullinated peptide) diagnostic test. The test can use a non-invasive saliva sample or a fingerstick sample. The availability of this test will facilitate early clinical stratification of rheumatoid arthritis and the implementation

On June 4, 2021 the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of CovAb SARS-CoV-2 Ab Test pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). Device: CovAb SARS-CoV-2 Ab Test EUA Number: EUA210017 Company: Diabetomics, Inc. Indication: Qualitative detection of total

Diabetomics developed the first rapid point-of-care test for C-peptide estimation. The Insudex® C-peptide POC test has a wide dynamic range and sensitivity comparable to a laboratory-based predicate assay. The availability of a rapid, simple-to-use POC test for C-peptide will facilitate staging of presymptomatic T1D and differential diagnosis of late-onset T1D, LADA, and MODY. Rao et al. Journal

A large, independent and prospective study in a low-resource setting demonstrated Lumella Preeclampsia rapid point-of-care test clinical utility for diagnosis of preeclampsia. Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting: a prospective Southeast Asian population study